Guinea-Bissau's health minister, Quinhin Nantote, publicly denied that the country approved a controversial hepatitis B vaccine trial in newborns — a study that would enroll 14,000 babies, withhold vaccination from half of them for six weeks, and track whether bad things happen. The study does not test vaccine safety or efficacy. It investigates 'nonspecific' health outcomes like overall mortality, a framing championed by Robert F. Kennedy Jr, the US health secretary and longtime anti-vaccine activist. The denial matters because members of a Danish research ethics committee were told that Guinea-Bissau had approved an updated study design — information that influenced their vote to proceed. At least four committee members resigned after approval was fast-tracked. The committee's own rules had to be rewritten because randomized controlled trials were outside its purview. When members asked for documentation of the Guinea-Bissau approval, none was provided. The trial is the brainchild of Danish researchers Peter Aaby and Christine Stabell Benn, who run the Bandim Health Project in Guinea-Bissau. Their decades of research have come under sharp scrutiny: a co-authored analysis found that 24 of 25 Aaby-Benn studies had no significant findings, with the researchers accused of selectively publishing results that support their viewpoint. Danish researcher Charlotte Strøm called their methodology 'problematic, questionable, and unethical,' saying they 'literally decide on the results themselves.' The structural absurdity is hard to miss. Denmark — where infants born to hepatitis B-negative parents don't receive the shot, where the virus is rare, and where robust healthcare systems track outcomes precisely — would be the ideal location for such a study. Instead, it was proposed for Guinea-Bissau, a country with widespread hepatitis B, a transitional military government following a November coup, and resource constraints that make comprehensive medical monitoring difficult. The study would cost $1.6 million in US CDC funding, matched by private money from the Pershing Square Foundation and Bluebell Foundation. Meanwhile, it would cost approximately $13,200 to vaccinate every newborn in Guinea-Bissau through UNICEF and Gavi. The extraction circuit is unusually legible. US political actors seeking to validate anti-vaccine ideology fund a trial in a low-income African nation using Danish researchers whose work has been discredited — a trial that could not be conducted in Denmark or the US because ethics boards would block it. Guinea-Bissau's children bear the biological risk. The researchers get publications. Kennedy gets a talking point. The WHO has offered to help Guinea-Bissau roll out universal hepatitis B birth-dose vaccination instead. Guinea-Bissau's pushback has been consistent. The foreign minister said flatly in February: 'It's not going to happen, period.' The country requested expert evaluation from the Africa CDC. Emory University researcher BK Titanji noted that even her survey research in Cameroon requires extensive documented approval — making the absence of any verifiable authorization from Guinea-Bissau for a medical trial on newborns a glaring procedural failure. The HHS told Reuters 'the study has not been approved' but has not responded to the Guardian's questions. The CDC has again set aside $1.6 million for the trial this year. Whether the funding persists despite the denial from Guinea-Bissau will reveal whether this was ever about science or always about ideology.
